LOGIN  |  REGISTER
Amneal Pharmaceuticals
C4 Therapeutics

LifeMD to Report Second Quarter 2023 Financial Results on August 9

July 26, 2023 | Last Trade: US$5.08 0.14 -2.68

NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended June 30, 2023 after the close of the U.S. financial markets on August 9, 2023 and will host a conference call beginning at 4:30 p.m. Eastern time.

Conference Call & Webcast Details

Date:Wednesday, August 9th
Time:4:30 p.m. Eastern Time
Toll-Free Dial-In:1-877-704-4453
International Dial-In:1-201-389-0920
Conference ID:13739131
Live & Archived Webcast:Link

About LifeMD

LifeMD is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men’s and women’s health, allergy & asthma, and dermatological conditions. By leveraging its proprietary technology platform, 50-state affiliated medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch healthcare that is affordable to anyone. To learn more, go to LifeMD.com.

Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact
Marc Benathen, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB